1. "2015"
Formats
  1. Journal Article (2716)
  2. Meeting Abstract (1680)
  3. Book Section (364)
  4. Conference Paper (26)
  5. Book Whole (19)
  6. Review (2)
  7. Research Letter (1)
Groups
  1. Department of Medicine (1855)
  2. GSK Faculty (1116)
  3. Solid Tumor Oncology Division (1035)
  4. Surgery (883)
  5. Survivorship Research (752)
  6. Center for Hematologic Malignancies (746)

More Groups

People
  1. William Travis (102)
  2. Michael Berger (96)
  3. Clifford Hudis (85)
  4. Marc Ladanyi (79)
  5. Jedd Wolchok (68)
  6. Britta Weigelt (67)

More People

Years
  1. 2015 (4808)
Publications
  1. Journal of Clinical Oncology (475)
  2. Blood (224)
  3. Cancer Research (168)
  4. Modern Pathology (125)
  5. Laboratory Investigation (112)
  6. International Journal of Radiation Oncology, Biology, Physics (91)

More Publications

Publishers
  1. Elsevier Inc. (581)
  2. American Society of Clinical Oncology (508)
  3. Springer (380)
  4. Nature Publishing Group (301)
  5. American Association for Cancer Research (263)
  6. American Society of Hematology (228)

More Publishers

Results (4808)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The DASH Study: A phase 1b study of dalantercept plus sorafenib in advanced hepatocellular carcinoma
    Meeting Abstract

    Abou-Alfa, G. K.; Miksad, R. A.; Gutierrez, M.; Tejani, M. A.; Sharma, M.; Sun, W. J.; Henderson, C. A.; Baron, A. D.; Olowokure, O. O.; Pearsall, R. S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426)
    Meeting Abstract

    Abou-Alfa, G. K.; Cheng, A. L.; Meyer, T.; El-Khoueiry, A. B.; Ikeda, M.; Chun, H. G.; Furuse, J.; Knox, J. J.; Okusaka, T.; Ping, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Trastuzumab interruption for treatment-induced cardiotoxicity in HER2 positive early breast cancer
    Meeting Abstract

    Yu, A. F.; Yadav, N. U.; Lung, B. Y.; Eaton, A. A.; Thaler, H. T.; Hudis, C. A.; Dang, C. T.; Steingart, R. M.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A phase 2, 2-stage, 2-cohort study of the oral PARP inhibitor BMN 673 in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO study)
    Meeting Abstract

    Turner, N. C.; Balmana, J.; Domchek, S. M.; Visco, F.; Zhang, C.; Lokker, N. A.; Lounsbury, D. L.; Robson, M. E.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
    Meeting Abstract

    Traina, T. A.; O'Shaughnessy, J.; Nanda, R.; Schwartzberg, L.; Abramson, V.; Cortes, J.; Peterson, A.; Tudor, I. C.; Blaney, M.; Steinberg, J. L.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A two-cohort, phase II, cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early breast cancer
    Meeting Abstract

    Swain, S. M.; Ewer, M. S.; Douthwaite, H.; Szado, T.; Waldron-Lynch, M.; Dang, C.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc
    Meeting Abstract

    Sikov, W. M.; Barry, W. T.; Hoadley, K. A.; Pitcher, B. N.; Singh, B.; Tolaney, S. M.; Kuzma, C. S.; Pluard, T. J.; Somlo, G.; Port, E. R.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Reliability of whole exome sequencing for assessing intratumor heterogeneity from breast tumor biopsies
    Meeting Abstract

    Shi, W. W.; Chagpar, A.; Jiang, T. T.; Lannin, D. R.; Killelea, B.; Horowitz, N.; Lim, R.; Platt, J.; Ng, C. K. Y.; Wali, V. B.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Ulaner, G.; Zamora, S.; Sterlin, V.; Iasonos, A.; Dickler, M. N.; Moynahan, M. E.; Hudis, C. A.; Baselga, J.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save